Apex Bioventures Acquisition Corp. To Seek Stockholder Approval To Liquidate and Dissolve

London Stock Exchange
Advanced charts
Premium community
Data download

Name	Symbol	Market	Type
ProShares Global Listed Private Equity	AMEX:PEX	AMEX	Exchange Traded Fund

Name

Symbol

Market

Type

ProShares Global Listed Private Equity

AMEX:PEX

AMEX

Exchange Traded Fund

	Price Change	% Change	Price	High Price	Low Price	Open Price	Traded	Last Trade
	0.1666	0.58%	28.835	28.88	28.76	28.86	1,537	21:15:00

Price Change

% Change

Price

High Price

Low Price

Open Price

Traded

Last Trade

0.1666

0.58%

28.835

28.88

28.76

28.86

1,537

21:15:00

Apex Bioventures Acquisition Corp. To Seek Stockholder Approval To Liquidate and Dissolve

05/03/2009 9:32pm

PR Newswire (US)

ProShares Global Listed ... (AMEX:PEX)
Historical Stock Chart

From Nov 2019 to Nov 2024

Click Here for more ProShares Global Listed ... Charts.

HILLSBOROUGH, Calif., March 5 /PRNewswire-FirstCall/ -- Apex Bioventures Acquisition Corporation (NYSE Alternext US: PEX) ("Apex") announced today that its board of directors has determined that Apex will not consummate a business combination in the time frame required by its Second Amended and Restated Certificate of Incorporation, and that it is advisable that Apex be dissolved. The Company will not proceed to liquidate until a plan of liquidation is approved by the Company and its stockholders. Apex will file a separate press release announcing the date of the stockholders meeting at which the board of directors will seek stockholder approval and the record date for such meeting. Forward-Looking Statements This press release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements are based on current expectations and are subject to numerous risks, assumptions and uncertainties, many of which change over time and are beyond Apex's control. Actual results may differ materially from those anticipated in any forward-looking statement and you should not place any undue reliance on such forward-looking statements. More detailed information about Apex and risk factors that may affect the realization of forward-looking statements, including forward-looking statements in this press release, is set forth in Apex's filings with the Securities and Exchange Commission. Apex urges investors and security holders to read those documents free of charge at the Commission's web site at http://www.sec.gov/. Interested parties may also obtain these documents free of charge from Apex. Forward-looking statements speak only as to the date they are made, and except for any obligation under the U.S. federal securities laws, Apex undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise. DATASOURCE: Apex Bioventures Acquisition Corporation CONTACT: Darrell J. Elliott, Chairman and Chief Executive Officer, +1-604-924-0349, K. Michael Forrest, President and Chief Operating Officer, +1-650-344-3029, both of Apex Bioventures Acquisition Corporation

	Real-time Prices	Level 2
London Stock Exchange
Chi-X Europe
BATS Europe
Aquis Exchange
FTSE Indices
Euronext
New York Stock Exchange
NASDAQ
American Stock Exchange
Dow Jones Indices
Forex
Precious Metal

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

PEX ProShares Global Listed Private Equity